Valuation: Neothetics Inc

Market Cap 1.13M 985K 909K 839K 1.59M 107M 1.62M 10.86M 4.26M 52.93M 4.23M 4.14M 182M P/E 2024
-0.08x
P/E 2025 26.7x
Enterprise Value 55.54M 48.58M 44.81M 41.39M 78.53M 5.3B 79.85M 535M 210M 2.61B 209M 204M 8.97B EV / Sales 2024
2.43x
EV / Sales 2025 2.76x
Free-Float
100%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Chief Executive Officer 57 31/12/2017
Director of Finance/CFO 49 12/04/2023
Chief Operating Officer - -
Director TitleAgeSince
Chairman 57 -
Director/Board Member 67 31/12/2017
Director/Board Member 58 31/12/2017
Change 5-day change 1-year change 3-year change Capi.($)
-3.63%-6.12% - - 1.13M
-2.33%-2.09%+50.33%+162.29% 1,060B
-0.82%-2.30%+62.97%+61.11% 619B
-0.73%-4.98%+27.22%+84.46% 438B
+0.33%-1.17%+27.98%+26.90% 333B
-0.02%-2.85%+25.27%+44.88% 282B
-3.89%-11.22%+20.78%+26.07% 267B
+0.66%-1.42%-29.26%-39.30% 218B
-0.06%-2.88%+20.98%+61.70% 196B
-3.72%-1.10%+13.35%+71.53% 161B
Average -1.17%-3.25%+24.40%+55.51% 397.1B
Weighted average by Cap. -0.56%-2.96%+35.28%+81.27%

Financials

2024 2025
Net sales 19.36M 16.94M 15.62M 14.43M 27.38M 1.85B 27.84M 187M 73.3M 910M 72.7M 71.12M 3.13B 20.18M 17.65M 16.28M 15.04M 28.54M 1.92B 29.02M 195M 76.4M 948M 75.78M 74.13M 3.26B
Net income -8.86M -7.75M -7.15M -6.6M -12.53M -845M -12.74M -85.41M -33.54M -416M -33.27M -32.54M -1.43B 391K 342K 315K 291K 553K 37.29M 562K 3.77M 1.48M 18.37M 1.47M 1.44M 63.16M
Net Debt 45.84M 40.1M 36.98M 34.16M 64.81M 4.37B 65.9M 442M 174M 2.15B 172M 168M 7.4B 54.42M 47.6M 43.9M 40.55M 76.94M 5.19B 78.24M 525M 206M 2.56B 204M 200M 8.79B
Logo Neothetics Inc
Evofem Biosciences, Inc. is a commercial-stage biopharmaceutical company. The Company is commercializing its products to address unmet needs in women’s sexual and reproductive health. The Company’s first approved product, PHEXXI (lactic acid, citric acid, and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of over 12 pre-filled applicators and is applied 0-60 minutes before each act of intercourse. PHEXXI is a gel that works to prevent pregnancy without the use of hormones. PHEXXI prevents pregnancy by reducing sperm motility, inhibiting sperm from reaching the ovum to form a zygote. Using the PHEXXI telehealth platform, women can directly meet with a health care provider to determine their eligibility for a PHEXXI prescription. The Company also commercialized SOLOSEC (secnidazole) 2g oral granules, an antibiotic for the treatment of two sexual health diseases such as bacterial vaginosis and trichomoniasis.
Employees
-